Margaret F Zupa1, Ronald A Codario1,2, Kenneth J Smith3. 1. Division of Endocrinology & Metabolism, University of Pittsburgh, PA 15213, USA. 2. Division of Endocrinology, Veteran's Health Administration Pittsburgh Health System, PA 15240, USA. 3. University of Pittsburgh, Center for Research on Healthcare, PA 15213, USA.
Abstract
Aim: Perform a cost-effectiveness analysis of addition of subcutaneous semaglutide versus empagliflozin to usual treatment for patients with Type 2 diabetes and cardiovascular disease in US setting. Materials & methods: A Markov decision model estimated the impact of each strategy using cardiovascular complication rates based on EMPA-REG and SUSTAIN-6 trials. Modeled cohorts were followed for 3 years at 1-month intervals beginning at age 66. Results: Compared with empagliflozin, semaglutide resulted in cost of US$19,964 per quality-adjusted life-year gained. In one-way sensitivity analysis, only semaglutide cost >US$36.25/day (base case US$18.04) resulted in empagliflozin being preferred at a willingness-to-pay threshold of US$50,000/quality-adjusted life-year gained. Conclusion: For patients with Type 2 diabetes and cardiovascular disease, semaglutide is likely more cost-effective than empagliflozin added to usual treatment.
Aim: Perform a cost-effectiveness analysis of addition of subcutaneous semaglutide versus empagliflozin to usual treatment for patients with Type 2 diabetes and cardiovascular disease in US setting. Materials & methods: A Markov decision model estimated the impact of each strategy using cardiovascular complication rates based on EMPA-REG and SUSTAIN-6 trials. Modeled cohorts were followed for 3 years at 1-month intervals beginning at age 66. Results: Compared with empagliflozin, semaglutide resulted in cost of US$19,964 per quality-adjusted life-year gained. In one-way sensitivity analysis, only semaglutide cost >US$36.25/day (base case US$18.04) resulted in empagliflozin being preferred at a willingness-to-pay threshold of US$50,000/quality-adjusted life-year gained. Conclusion: For patients with Type 2 diabetes and cardiovascular disease, semaglutide is likely more cost-effective than empagliflozin added to usual treatment.
Authors: Juan José Gorgojo-Martínez; Samuel J P Malkin; Virginia Martín; Nino Hallén; Barnaby Hunt Journal: J Med Econ Date: 2019-11-18 Impact factor: 2.448
Authors: Virginia M Rosen; Douglas C A Taylor; Hemangi Parekh; Ankur Pandya; David Thompson; Andreas Kuznik; David D Waters; Michael Drummond; Milton C Weinstein Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981
Authors: Peter Gæde; Pierre Johansen; Christian Klyver Tikkanen; Richard Fulton Pollock; Barnaby Hunt; Samuel Joseph Paul Malkin Journal: Diabetes Ther Date: 2019-05-16 Impact factor: 2.945